ClinicalTrials.gg
Active, not recruitingNCT05132361Updated Nov 4, 2026

SELUTION4SFA Trial

An interventional study of SELUTION SLR™ 018 DEB and Plain (Uncoated) Balloon Angioplasty (PTA) in Peripheral Arterial Disease and Superficial Femoral Artery Stenosis, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 34 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Primary completion movedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
42nd of 373
300 · median 64
Started
2022
with 19 others
No phase
217 of 479
40 open now
Primary completion
2026-07
later than 20 of 100 live
Registered
377th of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 42nd largest by enrollment of the 373 interventional ones that give a count, is one of 20 that started in 2022, is one of 217 with no phase, reaches primary completion later than 20 of the 100 other live ones, and was the 377th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).

Read the detailed description

Prospective, multi-center, single blinded, 2:1 randomized, controlled, superiority clinical trial.

This study will enroll up to 300 randomized subjects, and up to 20 subjects in a parallel pharmacokinetic (pK) sub study, at up to 60 clinical sites in the United Stated (US), Europe (EU) and Asia. A minimum of 50% of randomized subjects will be enrolled in the US. No more than 45 subjects (15% of the total randomized cohort) can be enrolled in the randomized cohort at any single investigational site.

Randomized Cohort:

Up to 300 subjects who meet all eligibility criteria will be randomized 2:1 by permuted block method (stratified by site and adjunctive lesion preparation) to one of two treatment arms:

  • Intervention - treatment with SELUTION SLR™ 018 DEB
  • Control - treatment with commercially available PTA (uncoated balloon)

Pharmacokinetic (pK) Sub-study:

The pK substudy is a parallel registry consisting of up to 20 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. The separate PK substudy protocol details the schedule of evaluations and blood draws to characterize the pK plasma profile of sirolimus.

03

Conditions studied

  • Peripheral Arterial Disease
  • Superficial Femoral Artery Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinical Inclusion Criteria:

  1. Subject age is ≥ 18 years or minimum legal age as required by local regulations.
  2. >1 year in opinion of investigator.
  3. Documented ischemia with Rutherford classification category 2, 3 or 4.
  4. Target lesion(s) in the SFA or PPA.
  5. Able to walk without the assistance of a walker.
  6. Subject is willing and able to provide and comply with study procedures and required follow-up evaluations.
  7. Female subjects only: If female, then subjects of must have a negative pregnancy test ≤ 7 days before the procedure and be prepared to use effective for 12 months after treatment.

Angiographic Inclusion Criteria:

  1. Angiographic evidence that target lesion lies within the superficial femoral artery and/or proximal popliteal artery (P1 and P2 only).
  2. Angiographic evidence that the target lesion consists of either a de novo lesion or a non-stented restenotic lesion, or a combination of both, that meets one of the following criteria:

    A. A stenosis of 70-99% with lesion length between ≥3cm and \<20cm by visual estimation.

    B. A total (100%) occlusion with lesion length between ≥3cm and ≤10cm by visual estimation.

    C. A combination lesion (stenosis and total occlusion) must have a total lesion length between ≥3cm and \<20cm by visual estimation with an occluded segment that is ≤10cm by visual estimation.

    D. If multiple lesions are to be treated, then only 2 lesions may be included. The total combination of lengths must be between ≥3cm and \< 20cm by visual estimation, and there must be at least 5 cm of artery that is not to be treated between them.

  3. Target vessel reference diameter ≥4mm and ≤7mm.
  4. Patent arterial inflow (common iliac, external iliac, common femoral and profunda femoris arteries, and the proximal 2 cm of the SFA) free from significant lesion (defined as ≥50% stenosis) as confirmed on angiography.

    Note: Where required, inflow iliac arteries (common and external iliac arteries only) must be successfully treated during the index procedure. Completion angiography must confirm successful treatment of inflow disease (≤30% residual stenosis, no distal embolization, and no Grade C or greater dissection ) prior to pre-dilation and randomization of the target lesion(s). Drug-eluting devices are not allowed for treatment of the occluded inflow iliac arteries.

  5. Angiographic evidence of adequate distal run off (defined as ≤50% stenosis) in one or more tibial arteries on initial angiography, and if applicable, after completion of inflow artery treatment.

Note: Treatment of outflow disease is permitted during the index procedure. Drug-eluting devices are not allowed for outflow treatment.

PK Sub-Study Inclusion Criteria:

Subjects must meet all of the main protocol inclusion criteria to participate in the PK sub-study. Subjects must also meet the following additional PK sub-study inclusion criteria:

1. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.

Clinical Exclusion Criteria:

  1. Other surgical or endovascular procedure in the target limb that occurred within 14 days prior to index procedure or is planned for within 30 days following index procedure, with exception for diagnostic angiography.
  2. Inability to tolerate dual antiplatelet therapy.
  3. Known or allergy to Sirolimus or other pharmacologic agents, such as contrast agent, which are required for the procedure and which cannot be adequately pre-treated.
  4. Stroke or MI within 3 months of enrollment.
  5. Symptom onset less than 14 days prior to index procedure (acute limb ischemia).
  6. Lower limb disease in the contralateral leg that requires treatment at the index procedure, or, that is planned within 14 days prior to the index procedure or within 30 days after the index procedure.
  7. Prior vascular surgery (including bypass and endarterectomy) of abdominal aorta, iliac arteries, or arteries of the index limb.
  8. Non-atherosclerotic disease of the index limb (including aneurysmal disease, vasculitis, Buerger's disease)
  9. Target lesion requires treatment with alternative therapies such as thrombolysis, thrombus aspiration, cutting/scoring/contoured balloon, stenting, laser, cryoplasty, intravascular lithotripsy, brachytherapy, re-entry device).
  10. Subject has target lesion(s) that require treatment via pedal site.
  11. Subject has target lesion(s) that require access via upper extremity arteries.
  12. Hypercoagulable state or disorder present, or coagulopathy present, including count less than 80,000 per microliter.
  13. Chronic renal insufficiency (dialysis dependent, or serum creatinine >2.5 mg/dL within 30 days of index procedure).
  14. Systemic infection (WBC > 12,000 and febrile) or known immune compromise.
  15. Breast-feeding woman.
  16. Currently participating in another drug or device study that has not completed primary endpoint follow-up.

Angiographic Exclusion Criteria:

  1. Presence of a previously placed stent in the treated artery.
  2. Failure to successfully cross the target lesion.
  3. Residual stenosis ≥30% after pre-dilatation.

PK Sub-Study Exclusion Criteria:

  1. Subjects must meet none of the main protocol exclusion criteria (Section 6.1.2 of the main protocol) to participate in the PK sub-study. Subjects will be excluded if any of the following additional PK sub-study exclusion criteria are met:
  2. Any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device has been placed/used in any part of the body within 3 months prior to the index procedure including non-target lesion(s) treated during the index procedure.
  3. Planned intervention with any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device anywhere in the body within 6 months after the index procedure. Note: staged procedures >30 days after index procedure (Exclusion #20 and #22 of the main protocol) are permitted only in the main protocol, and are not permitted in this PK sub-study.
  4. The subject is taking or has taken within the last 3 months any limus family medication(s) for any reason.
  5. Subjects who are taking strong Inhibitors within 14 days before the index procedure or plan to take the strong inhibitors during the study period. Strong inhibitors include: cobicistat; ritonavir; indinavir and ritonavir; itraconazole; ketoconazole; lopinavir and ritonavir; paritaprevir and ritonavir and ombitasvir (and/or dasabuvir); posaconazole; saquinavir and ritonavir; tipranavir and ritonavir; elvitegravir and ritonavir; telithromycin; voriconazole; ceritinib; clarithromycin; idealalisib; nefazodone; nelfinavir.
  6. Subjects who are taking strong CYP3A4 Inducers within 14 days before the index procedure or plan to take the strong inducers during the study period. Strong inducers include apalutamide; carbamazepine; enzalutamide; ivosidenib; lumacaftor and ivacaftor; mitotane; phenytoin; rifampin; St. John's wort.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    SELUTION SLR™ 018 DEB

    Treatment with Selution SLR drug eluting balloon to apply long term (\>90 days) local treatment with sirolimus

    Device: SELUTION SLR™ 018 DEB

  • Active comparator
    Plain (Uncoated) Balloon Angioplasty (PTA)

    Opening artery only by dilatation with an temporary inserted and inflated balloon.

    Device: Plain (Uncoated) Balloon Angioplasty (PTA)

Interventions

  • DeviceSELUTION SLR™ 018 DEB

    a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.

  • DevicePlain (Uncoated) Balloon Angioplasty (PTA)

    a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint

    The primary efficacy endpoint is primary patency of the target lesion defined as freedom from ALL of the following outcomes evaluated at 12 months post procedure: * Clinically driven target lesion revascularization (CD-TLR, defined as re-intervention of target lesion(s) due to recurrent, persistent, or worsening symptoms and angiographic restenosis (≥ 50% diameter stenosis) of target lesion by ACL measurement) and * Restenosis as determined by core lab adjudicated duplex ultrasound peak systolic velocity ratio of \>2.4 or occlusion of the target lesion.

    Time frame: 12 months

  2. Primary Safety Endpoint

    The primary safety endpoint is the freedom from ALL of the following adverse events: * All-cause perioperative death (POD) \[evaluated at 30 days\] and * Target limb major (above-the-ankle) amputation \[evaluated at 12 months\] and * Clinically driven target lesion revascularization (CD-TLR) \[evaluated at 12 months\]

    Time frame: 30 days or 12 months

  3. PK Sub-Study Primary Endpoint

    The primary endpoints of the sub-study are the PK parameters of C(max), T(max), AUC(last), and MRT(last) that will be used to determine the pharmacokinetic profile of Sirolimus after administration of the SELUTION SLR 018 DEB.

    Time frame: 6 months

Secondary outcomes

  1. Powered Secondary Endpoints

    If both primary endpoints are met, the following endpoint will be tested for superiority in a sequential manner: • Clinically driven target lesion revascularization (CD-TLR) \[evaluated at 12 months\]

    Time frame: 12 months

  2. Secondary Performance Endpoints

    * Device success, defined as successful delivery, balloon inflation, deflation, and retrieval of the intact investigational device \[evaluated post-procedure\]. * Procedural (technical) success, defined as device success and residual diameter stenosis ≤ 30% on completion angiography by core lab assessment \[evaluated post-procedure\]. * Clinical success, defined as procedural success without procedural complications (death, above-ankle target limb amputation, thrombosis of the target lesion or TLR) prior to discharge (evaluated at discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first).

    Time frame: Immediately following the procedure

  3. Secondary Safety Endpoints

    * Major adverse limb events (MALE): Major adverse limb events (MALE), defined as the composite of major (above-the-ankle) amputation or major reintervention (new bypass graft, jump/interposition graft revision, thrombectomy/thrombolysis) of the index limb. * Major cardiovascular events: defined as the composite of cardiovascular death, myocardial infarction (MI), and stroke. * All-cause mortality. * Major amputation, defined as above-the-ankle amputation of the target limb. * Amputation-free survival, defined as freedom from all-cause mortality and major amputation. * Target lesion thrombosis by angiographic or DUS core laboratory adjudication

    Time frame: 1, 6, and 12 months, and 2-5 years

  4. Secondary Efficacy Endpoints

    The following exploratory secondary endpoints will be assessed at discharge and at 1, 6, and 12 months, and 2-5 years (unless otherwise indicated). Detailed descriptions of these endpoints are provided individually under the corresponding Secondary Outcome Measures: * Primary sustained clinical improvement * Secondary sustained clinical improvement * Lesion primary patency * Lesion Primary assisted patency * Lesion secondary-assisted patency * Freedom from CD-TLR and binary restenosis * Any TLR * CD-TLR * Clinically driven Target Vessel Revascularization (TVR) * Change in Rutherford category * Change in ankle brachial index (ABI) * Change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ)

    Time frame: 1, 6, and 12 months, and 2-5 years

  5. Primary sustained clinical improvement

    A secondary efficacy endpoint defined as freedom from target limb major amputation and CD-TLR AND increase in Rutherford category from baseline.

    Time frame: 1, 6, and 12 months, and 2-5 years

  6. Secondary sustained clinical improvement

    A secondary efficacy endpoint defined as freedom from target limb major amputation AND increase in Rutherford category from baseline. * Major amputation, defined as above-the-ankle amputation of the target limb. * Amputation-free survival, defined as freedom from all-cause mortality and major amputation.

    Time frame: 1, 6, and 12 months, and 2-5 years

  7. Lesion primary patency

    A secondary efficacy endpoint defined as freedom from lesion re-intervention AND freedom from a DS \>50% restenosis assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS (as determined by a DUS peak systolic velocity ratio \[PSVR\] of ≤ 2.4)

    Time frame: 1, 6, and 12 months, and 2-5 years

  8. Lesion Primary assisted patency

    A secondary efficacy endpoint defined as freedom from a DS\>50% restenosis assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS (as determined by a DUS peak systolic velocity ratio PSVR of ≤ 2.4) - irrespective of interventions for stenoses. Lesion Secondary patency, defined as freedom from lesion re-intervention, AND freedom from permanent occlusion (at the last follow-up imaging) assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS.

    Time frame: 1, 6, and 12 months, and 2-5 years

  9. Lesion secondary-assisted patency

    A secondary efficacy endpoint defined as freedom from permanent occlusion (at the last follow-up imaging) assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS - irrespective of interventions for stenoses

    Time frame: 12 and 24 months

  10. Freedom from CD-TLR and binary restenosis

    A secondary efficacy endpoint as determined by the DCL \[at 1, 3, 6, 12, 24, 36 months\]

    Time frame: 1, 3, 6, 12, 24, 36 months

  11. Any TLR

    A secondary efficacy endpoint defined as any re-intervention of target lesion(s).

    Time frame: 1, 6, and 12 months, and 2-5 years

  12. CD-TLR

    A secondary efficacy endpoint defined as re-intervention of target lesion(s) due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target lesion by ACL measurement.

    Time frame: 1, 6, and 12 months, and 2-5 years

  13. Clinically driven Target Vessel Revascularization (TVR)

    A secondary efficacy endpoint defined as re-intervention of target vessel due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target vessel by ACL measurement.

    Time frame: 1, 6, and 12 months, and 2-5 years

  14. Change in Rutherford category

    A secondary efficacy endpoint from baseline \[at 1, 6, 12, 24 and 36 months\]

    Time frame: 1, 6, 12, 24 and 36 months

  15. Change in ankle brachial index (ABI)

    A secondary efficacy endpoint defined as change in ankle brachial index (ABI) from baseline.

    Time frame: 12 and 24 months

  16. Change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ)

    A secondary efficacy endpoint defined as change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ) from baseline.

    Time frame: 1, 6, 12, 24 and 36 months

  17. Secondary Imaging endpoints (DCL adjudicated):

    * Primary duplex-defined binary restenosis - Peak Systolic Velocity Ratio (PSVR)\>2.4. * Alternate duplex-defined binary restenosis - Peak Systolic Velocity Ratio (PSVR)\>3.4.

    Time frame: 12 and 24 months

  18. Secondary Quality of life and health economic assessments (1)

    • Change in EQ-5D score from baseline. OBS.: Following EuroQol terminology: Scores are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead.

    Time frame: 12 months

  19. Secondary Quality of life and health economic assessments (2)

    • Days of target lesion-related hospitalization at 12 months.

    Time frame: 12 months

  20. PK Sub-Study Secondary Endpoint

    If calculations are valid, additional PK parameters of AUC(inf), Cl, Vz, Vss, and half-life. Other PK parameters such as dose normalized Cmax and AUC will be considered if appropriate.

    Time frame: 6 months

07

Study locations

34 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jul 2026, 43 months.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 43 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 24, 2021
StartActual
Dec 1, 2022
Primary completionActual
Jul 25, 2026was Jun 2026
CompletionEst.
Dec 1, 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites removed
Show 4 removed
  • Heart Care Centers Research Foundation · Palos Park, United States
  • MedStar Health Research Institute · Hyattsville, United States
  • Cleveland Clinic · Cleveland, United States
  • Texas Cardiac and Vascular Institute San Antonio · San Antonio, United States
Nov 4, 2026
Primary completion
Jun 24, 2026→Jul 25, 2026 (actual)
Nov 4, 2026
Primary outcomes
1 edited, 3 removed, 2 description edited
What changed in the outcomes
  • EditedPK Sub-Study Primary Endpoint: C(max)Time frame: 6 months
  • RemovedPK Sub-Study Primary Endpoint: T(max)Time frame: 6 months
  • RemovedPK Sub-Study Primary Endpoint: AUC(last)Time frame: 6 months
  • RemovedPK Sub-Study Primary Endpoint MRT(last)Time frame: 6 months
  • DescriptionPrimary Efficacy Endpoint: how it is measured was reworded
  • DescriptionPrimary Safety Endpoint: how it is measured was reworded
Nov 4, 2026
Secondary outcomes
6 edited, 3 added, 12 removed, 3 description edited
What changed in the outcomes
  • EditedPrimary assistedLesion primary patencyTime frame: 12 and 24 months → 1, 6, and 12 months, and 2-5 years
  • EditedSecondaryLesion secondary-assisted patencyTime frame: 12 and 24 months
  • EditedChange in Rutherford categoryTime frame: 1, 6, 12, 24 and 36 months
  • EditedAnkleChange in ankle brachial index (ABI)Time frame: 12 and 24 months
  • EditedPK Sub-Study Secondary Endpoint: AUC(inf)Time frame: 6 months
  • ChangedBefore Walking capacityNow Change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ)Time frame: 1, 6, 12, 24 and 36 months
  • AddedSecondary Performance EndpointsTime frame: Immediately following the procedure
  • AddedSecondary Efficacy EndpointsTime frame: 1, 6, and 12 months, and 2-5 years
  • AddedLesion Primary assisted patencyTime frame: 1, 6, and 12 months, and 2-5 years
  • RemovedDevice successTime frame: Immediately following the procedure
  • RemovedProcedural (technical) successTime frame: Immediately following the procedure
  • RemovedClinical successTime frame: Discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first
  • RemovedMajor amputationTime frame: 1, 6, and 12 months, and 2-5 years
  • RemovedAmputation-free survivalTime frame: 1, 6, and 12 months, and 2-5 years
  • RemovedTarget lesion thrombosisTime frame: 1, 6, and 12 months, and 2-5 years
  • RemovedPK Sub-Study Secondary Endpoint: ClTime frame: 6 months
  • RemovedPK Sub-Study Secondary Endpoint: VzTime frame: 6 months
  • RemovedPK Sub-Study Secondary Endpoint: VssTime frame: 6 months
  • RemovedPK Sub-Study Secondary Endpoint: half-lifeTime frame: 6 months
  • RemovedPK Sub-Study Secondary Endpoint: C(max)Time frame: 6 months
  • RemovedPK Sub-Study Secondary Endpoint: AUCTime frame: 6 months
  • DescriptionFreedom from CD-TLR and binary restenosis: how it is measured was reworded
  • DescriptionPowered Secondary Endpoints: how it is measured was reworded
  • DescriptionSecondary Safety Endpoints: how it is measured was reworded
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    4 sites removed
    Show 4 removed
    • Heart Care Centers Research Foundation · Palos Park, United States
    • MedStar Health Research Institute · Hyattsville, United States
    • Cleveland Clinic · Cleveland, United States
    • Texas Cardiac and Vascular Institute San Antonio · San Antonio, United States
    Primary completion Jun 24, 2026→Jul 25, 2026 (now actual)
    Primary outcomes 1 edited, 3 removed, 2 description edited
    What changed in the outcomes
    • EditedPK Sub-Study Primary Endpoint: C(max)Time frame: 6 months
    • RemovedPK Sub-Study Primary Endpoint: T(max)Time frame: 6 months
    • RemovedPK Sub-Study Primary Endpoint: AUC(last)Time frame: 6 months
    • RemovedPK Sub-Study Primary Endpoint MRT(last)Time frame: 6 months
    • DescriptionPrimary Efficacy Endpoint: how it is measured was reworded
    • DescriptionPrimary Safety Endpoint: how it is measured was reworded
    Secondary outcomes 6 edited, 3 added, 12 removed, 3 description edited
    What changed in the outcomes
    • EditedPrimary assistedLesion primary patencyTime frame: 12 and 24 months → 1, 6, and 12 months, and 2-5 years
    • EditedSecondaryLesion secondary-assisted patencyTime frame: 12 and 24 months
    • EditedChange in Rutherford categoryTime frame: 1, 6, 12, 24 and 36 months
    • EditedAnkleChange in ankle brachial index (ABI)Time frame: 12 and 24 months
    • EditedPK Sub-Study Secondary Endpoint: AUC(inf)Time frame: 6 months
    • ChangedBefore Walking capacityNow Change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ)Time frame: 1, 6, 12, 24 and 36 months
    • AddedSecondary Performance EndpointsTime frame: Immediately following the procedure
    • AddedSecondary Efficacy EndpointsTime frame: 1, 6, and 12 months, and 2-5 years
    • AddedLesion Primary assisted patencyTime frame: 1, 6, and 12 months, and 2-5 years
    • RemovedDevice successTime frame: Immediately following the procedure
    • RemovedProcedural (technical) successTime frame: Immediately following the procedure
    • RemovedClinical successTime frame: Discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first
    • RemovedMajor amputationTime frame: 1, 6, and 12 months, and 2-5 years
    • RemovedAmputation-free survivalTime frame: 1, 6, and 12 months, and 2-5 years
    • RemovedTarget lesion thrombosisTime frame: 1, 6, and 12 months, and 2-5 years
    • RemovedPK Sub-Study Secondary Endpoint: ClTime frame: 6 months
    • RemovedPK Sub-Study Secondary Endpoint: VzTime frame: 6 months
    • RemovedPK Sub-Study Secondary Endpoint: VssTime frame: 6 months
    • RemovedPK Sub-Study Secondary Endpoint: half-lifeTime frame: 6 months
    • RemovedPK Sub-Study Secondary Endpoint: C(max)Time frame: 6 months
    • RemovedPK Sub-Study Secondary Endpoint: AUCTime frame: 6 months
    • DescriptionFreedom from CD-TLR and binary restenosis: how it is measured was reworded
    • DescriptionPowered Secondary Endpoints: how it is measured was reworded
    • DescriptionSecondary Safety Endpoints: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05132361
Lead sponsor
M.A. Med Alliance S.A.
Collaborators
NAMSA, Cordis US Corp.
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Dec 1, 2022
Primary completion
Jul 25, 2026
Completion
Dec 1, 2030 (estimated)
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion